Merck to Acquire Terns Pharmaceuticals for $6.7 Billion in Bold Oncology Expansion

WASHINGTON – In a move that signaled a massive consolidation within the biotechnology sector, pharmaceutical giant Merck & Co. announced Wednesday its definitive agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion. 

The deal, valued at $53 per share in cash, represents a strategic maneuver by Merck to bolster its hematology and oncology pipeline as it prepares for the impending "patent cliff" of its blockbuster immunotherapy, Keytruda, later this decade.

A Best-in-Class Contender for Leukemia

The centerpiece of the acquisition is Terns’ lead candidate, TERN-701, an investigational oral allosteric BCR-ABL1 inhibitor currently in Phase 1 clinical trials for chronic myeloid leukemia (CML). Early data from the CARDINAL study has already turned heads in the medical community, showing a 75% major molecular response rate in patients who had previously failed other treatments.

Industry analysts suggest that TERN-701 could disrupt the current treatment landscape, potentially challenging the market dominance of Novartis’ Scemblix. Merck CEO Robert Davis emphasized that the acquisition "builds on our growing presence in hematology," noting that the oral nature and high selectivity of the Terns compound offer a potentially best-in-class profile for safety and convenience.

Navigating a Volatile Market

The acquisition comes at a pivotal moment for the biotech industry in 2026. While several drugmakers are facing regulatory scrutiny over marketing claims—most notably the recent FDA warning issued to ImmunityBio regarding its cancer drug Anktiva—Merck’s acquisition of Terns Pharmaceuticals underscores a "quality-over-quantity" trend in M&A activity.

"This is one of the most disciplined deals we’ve seen Merck make in recent years," noted an analyst from BMO Capital Markets. "By securing Terns before the asset enters pivotal Phase 3 trials, Merck is betting big on the 'unprecedented' clinical profile of their leukemia candidate."

Key Details of the Deal

• Total Equity Value: Approximately $6.7 billion.

• Offer Price: $53.00 per share (a significant premium over recent volume-weighted averages).

• Expected Closing: Second quarter of 2026.

• Termination Fee: $235 million payable by Terns under specific conditions.

The transaction is expected to be completed following customary closing conditions, including antitrust approvals.

Following the announcement, shares of Terns Pharmaceuticals surged, reflecting investor confidence in the valuation and the strategic fit within Merck's expanding cancer division.